Hepatoid Gastric Adenocarcinoma with Adenosquamous Overlap, a Diagnostic Challenge in a Poor-Prognosis Tumor: Case Report
DOI:
https://doi.org/10.22516/25007440.1394Keywords:
Gastric cancer, epidemiology, prognosis, health classificationsAbstract
Introduction: Gastric cancer (GC) remains one of the most lethal malignancies worldwide and represents a major global public health concern. The most common histological subtypes are classically classified as intestinal and diffuse. According to the World Health Organization (WHO) classification, gastric adenocarcinomas are further categorized as papillary, mucinous, poorly cohesive, mixed, and tubular types. Hepatoid gastric adenocarcinoma is considered an exceptionally rare tumor, with an incidence ranging from 0.3% to 1.0% of all gastric cancers.
Clinical Case: A 68-year-old male patient was diagnosed with hepatoid adenocarcinoma with adenosquamous overlap. He presented with epigastric pain and three episodes of coffee-ground emesis. Upper gastrointestinal endoscopy was performed, and biopsy samples were obtained. Based on histopathological and immunohistochemical analysis, the tumor was classified as a hepatoid subtype with adenosquamous overlap.
Discussion and Conclusion: This case represents a true clinical and histopathological diagnostic challenge, as definitive characterization was achieved only through immunohistochemistry. Fundamental aspects of these histopathological subtypes are described, highlighting their low incidence and potential tumor histogenesis, with particular emphasis on their aggressive biological behavior and poor prognosis.
Downloads
References
International Agency for Research on Cancer. Cancer Today Stomach - The Global Cancer Observatory 2022[Internet]. IARC; 2024 [consultado el 31 de mayo de 2025]. Disponible en: https://gco.iarc.who.int/media/globocan/factsheets/cancers/7-stomach-fact-sheet.pdf
Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. 2022;47:101404. https://doi.org/10.1016/j.eclinm.2022.101404
de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180-90. https://doi.org/10.1016/S2214-109X(19)30488-7
Han Z, Liu J, Zhang W, Kong Q, Wan M, Lin M, et al. Cardia and non-cardia gastric cancer risk associated with Helicobacter pylori in East Asia and the West: A systematic review, meta-analysis, and estimation of population attributable fraction. Helicobacter. 2023;28(2):e12950. https://doi.org/10.1111/hel.12950
Yang L, Kartsonaki C, Yao P, de Martel C, Plummer M, Chapman D, et al. The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study. Lancet Public Health. 2021;6(12):e888-96. https://doi.org/10.1016/S2468-2667(21)00164-X
Zhao J, Zhao J, Du F, Zhang Y, Shen G, Zhu H, et al. Cardia and Non-Cardia Gastric Cancer Have Similar Stage-for-Stage Prognoses After R0 Resection: a Large-Scale, Multicenter Study in China. J Gastrointest Surg. 2016;20(4):700-7. https://doi.org/10.1007/s11605-016-3089-z
Park JC, Lee YC, Kim JH, Kim YJ, Lee SK, Shin SK, et al. Clinicopathological features and prognostic factors of proximal gastric carcinoma in a population with high Helicobacter pylori prevalence: a single-center, large-volume study in Korea. Ann Surg Oncol. 2010;17(3):829-37. https://doi.org/10.1245/s10434-009-0785-x
Piso P, Werner U, Lang H, Mirena P, Klempnauer J. Proximal versus distal gastric carcinoma--what are the differences? Ann Surg Oncol. 2000;7(7):520-5. https://doi.org/10.1007/s10434-000-0520-0
Saito H, Fukumoto Y, Osaki T, Fukuda K, Tatebe S, Tsujitani S, et al. Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg. 2006;30(10):1864-9. https://doi.org/10.1007/s00268-005-0582-z
Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354-62. https://doi.org/10.3748/wjg.v12.i3.354
Correa P, Camargo MC, Piazuelo MB. Overview and pathology of gastric cancer. En: Wang TC, Fox JG, Giraud AS (editores). The biology of gastric cancers. Nueva York, Estados Unidos: Springer; 2009. p. 1-24. https://doi.org/10.1007/978-0-387-69182-4_1
Kushima R. The updated WHO classification of digestive system tumours-gastric adenocarcinoma and dysplasia. Pathologe. 2022;43(1):8-15. https://doi.org/10.1007/s00292-021-01023-7
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-8. https://doi.org/10.1111/his.13975
WHO Classification Tumours Editorial Board. WHO classification of tumours: digestive system tumours. 5.a edición. Lyon, Francia: IARC Press; 2019.
Su JS, Chen YT, Wang RC, Wu CY, Lee SW, Lee TY. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review. World J Gastroenterol. 2013;19(3):321-7. https://doi.org/10.3748/wjg.v19.i3.321
Liu X, Sheng W, Wang Y. An analysis of clinicopathological features and prognosis by comparing hepatoid adenocarcinoma of the stomach with AFP-producing gastric cancer. J Surg Oncol. 2012;106(3):299-303. https://doi.org/10.1002/jso.23073
Wang Y, Sun L, Li Z, Gao J, Ge S, Zhang C, et al. Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. Gastric Cancer. 2019;22(6):1183-92. https://doi.org/10.1007/s10120-019-00965-5
Ling Q, Liu HL, Huang ST, Sun LF, Wu WW, Kudriashov V, et al. Clinicopathological features of hepatoid adenocarcinoma and non-hepatoid adenocarcinoma of the stomach: A systematic review and meta-analysis. Cancer Med. 2024;13(16):e70130. https://doi.org/10.1002/cam4.70130
Zeng XY, Yin YP, Xiao H, Zhang P, He J, Liu WZ, et al. Clinicopathological Characteristics and Prognosis of Hepatoid Adenocarcinoma of the Stomach: Evaluation of a Pooled Case Series. Curr Med Sci. 2018;38(6):1054-61. https://doi.org/10.1007/s11596-018-1983-1
Jiang J, Ding Y, Lu J, Chen Y, Chen Y, Zhao W, et al. Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach. Int J Biol Sci. 2022;18(14):5554-74. https://doi.org/10.7150/ijbs.71449
Zhou K, Wang A, Ao S, Chen J, Ji K, He Q, et al. The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis. BMC Cancer. 2020;20(1):671. https://doi.org/10.1186/s12885-020-07031-9
Zhang JF, Shi SS, Shao YF, Zhang HZ. Clinicopathological and prognostic features of hepatoid adenocarcinoma of the stomach. Chin Med J (Engl). 2011;124(10):1470-6.
Yang X, Wu Y, Wang A, Ma X, Zhou K, Ji K, et al. Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases. J Pathol Clin Res. 2024;10(1):e343. https://doi.org/10.1002/cjp2.343
Huang WP, Li LM, Li J, Yuan JH, Hou P, Liu CC, et al. Computed Tomography Features and Clinical Prognostic Characteristics of Hepatoid Adenocarcinoma of the Stomach. Front Oncol. 2021;11:772636. https://doi.org/10.3389/fonc.2021.772636
Nagai E, Ueyama T, Yao T, Tsuneyoshi M. Hepatoid adenocarcinoma of the stomach. A clinicopathologic and immunohistochemical analysis. Cancer. 1993;72(6):1827-35. https://doi.org/10.1002/1097-0142(19930915)72:6<1827::AID-CNCR2820720606>3.0.CO;2-8
Liu X, Cheng Y, Sheng W, Lu H, Xu X, Xu Y, et al. Analysis of clinicopathologic features and prognostic factors in hepatoid adenocarcinoma of the stomach. Am J Surg Pathol. 2010;34(10):1465-71. https://doi.org/10.1097/PAS.0b013e3181f0a873
Wei J, Ji K, Zhang Y, Zhang J, Wu X, Ji X, et al. Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach. Cell Oncol (Dordr). 2024;47(2):677-93. https://doi.org/10.1007/s13402-023-00892-9
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Revista colombiana de Gastroenterología

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

| Article metrics | |
|---|---|
| Abstract views | 606 |
| Galley views | 236 |
| PDF Views | 236 |
| HTML views | 0 |
| Other views | 0 |














